If you have been reading about cyclic peptide and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-06-27. Where a claim depends on a specific study, the study is described rather than over-claimed.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Handling guidance for melanotan II follows general practice for small synthetic peptides rather than a product-specific monograph. Lyophilized powder is typically kept at minus twenty degrees Celsius or colder, protected from light and moisture, because warmth and humidity accelerate degradation. Once reconstituted, solutions are usually refrigerated and used within a short window, as hydrolysis and microbial growth both become concerns. Repeated freeze-thaw cycles are generally avoided. These conventions come from laboratory peptide chemistry and not from formal stability studies on this specific compound.
Analytical confirmation of identity relies on mass spectrometry, most often coupled to liquid chromatography. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and provides a purity estimate based on peak area. Electrospray ionization mass spectrometry then confirms the expected molecular mass, while tandem mass spectrometry can map the fragment sequence. For research-grade material, these two techniques together form the standard minimum. Purity figures reported by vendors are frequently not traceable to an independent laboratory.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Free base; salt forms add to total mass |
| Molecular mass | About 1024 daltons | Calculated for the free base |
| Structural class | Cyclic heptapeptide | Contains D-phenylalanine and norleucine |
| Parent hormone | Alpha-melanocyte-stimulating hormone | Endogenous tridecapeptide of 13 residues |
| Receptor profile | Non-selective melanocortin agonist | Interacts with MC1R, MC3R, MC4R and MC5R |
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Melanotan-2 has not received marketing authorisation from major regulatory agencies for any therapeutic indication. Several jurisdictions classify it as a prescription-only medicine or a controlled substance when supplied for human use. Because approved products do not exist, material sold online usually sits outside pharmaceutical supply chains and formal quality oversight. Regulators have issued public notices describing the compound as unapproved. Enforcement varies, and the legal position differs between countries, which complicates any single general statement about its status.
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.
Melanocytes are the pigment-producing cells of the skin, and they carry melanocortin-1 receptors on their surface. When the receptor is activated, cyclic adenosine monophosphate rises inside the cell and raises the activity of enzymes such as tyrosinase, which increases melanin output. Melanotan-2 binds melanocortin-1 receptors in vitro and in animal models, and this binding is generally described as the basis for the tanning effect. Other receptors account for different effects: melanocortin-4 receptors contribute to appetite and erectile signalling, while melanocortin-3 and melanocortin-5 receptors contribute to energy balance and exocrine function.
Solid peptide material is generally stable when kept cold and dry. Common practice is storage at -20 degrees Celsius or lower, with desiccant and protection from light. Repeated freeze-thaw cycles and exposure to moisture are associated with degradation, aggregation, or loss of material. Once dissolved, stability depends on solvent, concentration, and temperature, and solutions are usually treated as short-lived unless stability data support longer periods. Handling notes typically emphasise minimising time at ambient temperature.
Identity and purity are assessed with chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the target peptide from related impurities and degradation products, and the resulting retention time is compared against a reference standard. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass. Amino acid analysis or peptide mapping can provide additional sequence-level confirmation when required. Results are only as reliable as the reference materials used alongside them.
Amane Waseda reported δD of oil samples in northeast Japan to increase from around −130‰ to around −110‰ with higher maturity. At low thermal maturity, dos Santos Neto and Hayes reported δD of saturate fraction of oil in Portiguar Basin derived from a lacustrine environment is -90‰, and from a marine-evaporitic environment is -120‰ to −135‰. Bulk analysis of oil, which yields a complex mixture of organic compounds, obscures much of the valuable information. Switching to compound-specific study greatly expanded our understanding of hydrogen isotopes of oil. Analyzing HIC at the compound level avoids problems from differences in exchange rates, simplifies sources and products relationships, and draws a much more detailed picture. δDs of n-alkanes are generally thought to be representative of oil as they are the major components. Schimmelmann et al. confirmed that alkane fractions have almost the same DHRs as whole oils. Depending on source material type and maturity, δD of n-alkanes can vary from −100‰ to −180‰. A common phenomenon of various oil and matured rock derived n-alkanes is a trend of increasing δD with chain length. For example, Li et al. analyzed oils from the Western Canada Sedimentary Basin and found δD increased between 20‰ and 40‰ from C13 to C27. This "isotope slope" is an artifact of kinetic fractionation associated with thermal cracking of carbon chains. This trend has been experimentally reproduced and theoretically modeled by Tang et al. N-alkanes are also known to preserve detailed information of source material. Li et al.
A few days later, on December 7, Webb engaged two hobbyists, Edgar Van Horn and Ernest Howatt, to photograph the carcass for posterity. At least two photographs were taken, one of the lateral view and one of the anterior view, showing the apparent arm stumps. The latter also included a man, likely DeWitt Webb himself, for scale. As the images were over-exposed, they were never published. These photographs were for a long time considered lost, and only drawings based on them, made by Alpheus Hyatt Verrill and published in the American Naturalist of April 1897, were known. However, one of the original images, showing the lateral view, was obtained by Gary Mangiacopra in 1994. It is clear that one of Verrill's drawings was based on this photograph. A simplified drawing of this image also appeared in the Hartford Daily Running of February 18, 1897. Around the same time, a certain Mr. Wilson wrote a memorandum to Webb, communicating the results of his observations made after having dug around the corpse. It read:
Mural Painting: cool, dry, glue, tempera, sgraffito Easel Painting and Altars: canvas, board, altarpiece Sculptural and Ornamental Materials: stone, mortar, stucco, bronze, terracotta, wood Golden, polychrome, furniture and expertizing Archaeological and ethnographic materials: flooring, tiles, ceramic tiles, glass, archaeological remains, tapestry, vestment, robes Graphic and Documentary: drawing, scroll, prints, book, photograph, manuscript The intervention Area of Architectural Heritage comprises:
Sources: en.wikipedia.org
Decalcification of small bone chunks in a 1-5% hydrochloric acid solution. If further decayed organic matter remains, a soak in 0.1 molar sodium hydroxide may be required. The isolated collagen is then freeze dried. Demineralisation of small bone chunks in sodium salt to separate collagen, which is then freeze-dried Demineralisation of powdered bone in 8% hydrochloric acid, slow hydrolysis in pH 3. If required, a further soak in 0.1 molar sodium hydroxide. The latter is most effective in the instance of very poorly preserved bone, although it also faces an increased risk of contamination by other organic matter. Consequently, the supposedly isolated sample should be analysed and only tested if the readings fall within an acceptable range; most mass spectrometers now include a gas analyser as well as a combustion chamber to streamline this process.
Liquefied gases, such as liquid nitrogen and liquid helium, are used in many cryogenic applications. Liquid nitrogen is the most commonly used element in cryogenics and is legally purchasable around the world. Liquid helium is also commonly used and allows for the lowest attainable temperatures to be reached. These liquids may be stored in Dewar flasks, which are double-walled containers with a high vacuum between the walls to reduce heat transfer into the liquid. Typical laboratory Dewar flasks are spherical, made of glass and protected in a metal outer container. Dewar flasks for extremely cold liquids such as liquid helium have another double-walled container filled with liquid nitrogen. Dewar flasks are named after their inventor, James Dewar, the man who first liquefied hydrogen. Thermos bottles are smaller vacuum flasks fitted in a protective casing. Cryogenic barcode labels are used to mark Dewar flasks containing these liquids, and will not frost over down to −195 degrees Celsius. Cryogenic transfer pumps are the pumps used on LNG piers to transfer liquefied natural gas from LNG carriers to LNG storage tanks, as are cryogenic valves.
=== Pollution remediation === NASA's microencapsulating technology enabled the creation of "Petroleum Remediation Product," (PRP) which safely cleans petroleum-based pollutants from water. PRP uses thousands of microcapsules—tiny balls of beeswax with hollow centers. Water cannot penetrate the microcapsule's cell, but oil is absorbed into the beeswax spheres as they float on the water's surface. Contaminating chemical compounds that originally come from crude oil (such as fuels, motor oils, or petroleum hydrocarbons) are caught before they settle, limiting damage to ocean beds. PRP microcapsules serve as nutrients to assist naturally occurring microbes in soil or water to biodegrade contaminants.
Sources: en.wikipedia.org
No regulatory agency has authorised melanotan-2 as a medicine for any indication. It circulates mainly as a research chemical or through unregulated channels. As a result, identity, purity and content are not independently guaranteed.
Melanotan-1, also called afamelanotide, is a linear analogue with greater selectivity for MC1R and has received approval in some jurisdictions for a specific photosensitivity disorder. Melanotan-2 is cyclic, less selective, and reaches central receptors more readily. The two are often confused in online discussion despite different pharmacology and regulatory status.
Alpha-MSH is an endogenous tridecapeptide derived from pro-opiomelanocortin. Melanotan-2 reproduces its core receptor-binding sequence inside a shortened, stabilised ring. The result is a molecule with a longer effective half-life and higher potency than the parent hormone.
The lyophilized powder is generally held at minus twenty degrees Celsius or below, away from light and moisture. Reconstituted solutions are typically refrigerated and used quickly. These practices derive from general peptide handling rather than a formal stability study.